Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia - Rossignol, J; Michallet, A-S; Oberic, L; Picard, M; Garon, A; Willekens, C; Dulery, R; Leleu, X; Cazin, B; Ysebaert, L (Leukemia, 2011)
Keywords: 692/699/249/1313; 692/699/67/1990/283/1895; 692/700/565/1436/1437; Adult; Aged; Aged, 80 and over; Analysis; Anemia; Anemia, Hemolytic, Autoimmune - drug therapy; Anemia, Hemolytic, Autoimmune - etiology; Anemia, Hemolytic, Autoimmune - mortality; Antibodies, Monoclonal, Murine-Derived - administration & dosage; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Aplasia; Autoimmune diseases; Autoimmune hemolytic anemia; Autoimmunity; Biological and medical sciences; Bone marrow; Cancer Research; Care and treatment; Chemotherapy; Chronic lymphocytic leukemia; Corticoids; Corticosteroids; Critical Care Medicine; Cyclophosphamide; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Cyclophosphamide - therapeutic use; Cytopenia; Development and progression; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Dexamethasone - therapeutic use; Diagnosis; Dosage and administration; Drug therapy; Drug Therapy, Combination; Female; Genetic aspects; Health aspects; Hematologic and hematopoietic diseases; Hematology; Hemoglobin; Hemolytic anemia; Humans; Immunotherapy; Intensive; Internal Medicine; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - complications; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphatic leukemia; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Oncology; original-article; Patients; Purpura, Thrombocytopenic, Idiopathic - drug therapy; Purpura, Thrombocytopenic, Idiopathic - mortality; Recurrence; Red-Cell Aplasia, Pure - drug therapy; Red-Cell Aplasia, Pure - mortality; Retrospective Studies; Risk factors; Rituximab; Splenectomy; Steroids; Targeted cancer therapy; Thrombocytopenia; Thrombocytopenia - drug therapy; Thrombocytopenia - mortality; France; RCD; AITP; chronic lymphocytic leukemia; PRCA; Evan's syndrome; AIHA; Antineoplastic agent; Autoimmunity; Autoimmune disease; Monoclonal antibody; Evans syndrome; Lymphoproliferative syndrome; Immunotherapy; Corticosteroid; Immunopathology; Drug combination; Dexamethasone; Hematology; Steroid hormone; Rituximab